Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

BACKGROUND The combination of ribavirin (RBV) and pegylated interferon (PEG-IFN) is effective in the treatment of chronic hepatitis C infection. Reducing the frequency of RBV intake from twice to once a day will improve compliance and opens up the opportunity to combine RBV with new and more specific direct-acting agents in one pill. Therefore, the purpose of this study was to evaluate the phar...

Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.

BACKGROUND A prolonged-release formulation of tacrolimus (Tacrolimus QD) was developed to allow once-daily dosing and to have similar safety and efficacy profiles to twice-daily tacrolimus (Tacrolimus BID). This study compared the pharmacokinetics (PK) and renal pathology by protocol biopsy in de novo living kidney transplant recipients treated with either low-dose Tacrolimus QD or Tacrolimus B...

Asenapine once daily versus twice daily: impact on patient acceptance in a randomized, open-label, 14-day clinical trial.

To the Editor: Asenapine is a newly approved, second-generation antipsychotic with demonstrated efficacy for the treatment of schizophrenia.1,2 However, the acceptance of asenapine is compromised in some patients by its associated daytime sleepiness. The US Food and Drug Administration recommended dose for asenapine as the acute treatment of schizophrenia is 5 mg twice daily,3 but its terminal ...

once daily combination regimen for hiv infection

Quick- and slow-release iron: a double-blind trial with a single daily dose regimen.

In a double-blind trial the response to treatment with Ferro-Gradume (a slow-release preparation of ferrous sulphate) has been compared in the same individuals with the response to ferrous fumarate in a single daily dose regimen using a similar dose of iron. No significant difference was found in the therapeutic response or in the incidence of side-effects between the two preparations.